Section A: Submissions for registration
The committee's advice was sought on one application seeking to extend the indication for the vaccine and also to register a new strength of this vaccine, and one application seeking to register an additional dosing schedule for the vaccine.
Further details of the ACV discussion and advice associated with this pre-market item may be released within the Australian Public Assessment Report (AusPAR). Please note that there is a delay between when an application is considered by the ACV and the publication of the AusPAR. To browse all AusPARs see AusPAR search.
Section B: Safety
No safety or pharmacovigilance issue was discussed.
Section C: Immunisation Programs
No matter related to the immunisation programs was discussed.
Further information
For further information on the ACV, please visit Advisory Committee on Vaccines or contact the ACV by email ACV@health.gov.au.